<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04071730</url>
  </required_header>
  <id_info>
    <org_study_id>2019-0183</org_study_id>
    <nct_id>NCT04071730</nct_id>
  </id_info>
  <brief_title>Effects of Immulina on Immune Measures</brief_title>
  <official_title>Effects of Immulina Dietary Supplementation on Innate and Adaptive Immune Measures in Normal Human Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Mississippi Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Mississippi Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This small, randomized, double blind, placebo controlled pilot study is aimed at determining&#xD;
      the effects of oral Immulina dietary supplementation on specific immune biomarkers in the&#xD;
      blood.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This small, randomized, double blind, placebo controlled pilot study is aimed at determining&#xD;
      the effects of four weeks of daily Immulina dietary supplementation (800 mg/day) versus four&#xD;
      weeks of daily placebo on natural killer (NK) cell numbers and/or natural killer (NK) cell&#xD;
      activity in human peripheral blood mononuclear cells collected from human research&#xD;
      participants who meet the trial's inclusion/exclusion criteria.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 3, 2019</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Natural Killer (NK) cell count</measure>
    <time_frame>4 weeks</time_frame>
    <description>Differences in NK cell counts from baseline to 4 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Natural Killer (NK) cell cytotoxic activity</measure>
    <time_frame>4 weeks</time_frame>
    <description>Differences in NK cell cytotoxic activity from baseline to 4 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokine profiles</measure>
    <time_frame>4 weeks</time_frame>
    <description>Differences in in-Vitro peripheral blood mononuclear cell (PBMC) culture supernatants' cytokine profiles from baseline to 4 weeks (IFN-α, IFN-γ, IL-1β, IL-2, IL-4, IL-6, Il-10, IL-12, Il-15 and TNFα)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune cell populations</measure>
    <time_frame>4 weeks</time_frame>
    <description>Differences in immune cell populations in PBMC from baseline to 4 weeks.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Effects of Immulina on Natural Killer Cells</condition>
  <arm_group>
    <arm_group_label>Immulina Dietary Supplementation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immulina Dietary Supplementation - 200 mg capsules; 800 mg/day; 2 (200 mg) capsules given by mouth in the morning and 2 (200 mg) capsules given by mouth in the evening for 4 weeks duration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo - inert capsules; 2 capsules given by mouth in the morning and 2 capsules given by mouth in the evening for 4 weeks duration</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Immulina Dietary Supplementation</intervention_name>
    <description>Immulina Dietary Supplementation is a highly standardized extract derived from various preparations of Spirulina, a cyanobacterium, marketed as a dietary supplement and has been utilized in several clinical studies describing its immunopotentiating properties.</description>
    <arm_group_label>Immulina Dietary Supplementation</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Immulina</other_name>
    <other_name>Spirulina</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Normal, generally healthy adults between ages 18-64 and who may or may not have a&#xD;
             controlled disease(s). Examples of controlled diseases are controlled Type-2 diabetes&#xD;
             mellitus, controlled hypertension, controlled allergic rhinitis, etc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Individuals with specific disease entities, which, in the opinion of the Principal&#xD;
             Investigator, could reasonably be assumed to have dysfunctional immune function as a&#xD;
             component of their illness. These include HIV, AIDS, uncontrolled asthma, uncontrolled&#xD;
             eczema, uncontrolled allergic rhinitis, uncontrolled urticaria, rheumatoid arthritis,&#xD;
             lupus, inflammatory bowel disease, multiple sclerosis, Type-1 diabetes mellitus,&#xD;
             Guillain-Barre syndrome, psoriasis, Grave's disease, Hashimoto's thyroiditis,&#xD;
             myasthenia gravis or vasculitis.&#xD;
&#xD;
          -  Individuals taking specific dietary supplements including probiotic, microalgae or&#xD;
             beta glucan containing dietary supplements, fermented food products (such as yogurt,&#xD;
             bean curd, etc.). If the potential participants reports usage of any of these&#xD;
             products, they will be asked if they would be willing to withhold products for 30 days&#xD;
             and then be re-screened for inclusion/exclusion criteria.&#xD;
&#xD;
          -  Individuals who are unwilling to refrain for the duration of the trial from taking the&#xD;
             specific dietary supplements and fermented food products including probiotic,&#xD;
             microalgae or beta glucan containing dietary supplements, fermented food products&#xD;
             (such as yogurt, bean curd, etc.).&#xD;
&#xD;
          -  Pregnant females (because baseline immune responses, are altered by pregnancy)&#xD;
&#xD;
          -  Individuals unable to speak, understand and read English&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gailen D Marshall, Jr., MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Study Principal Investigator</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Denise D Montgomery, MT(ASCP)</last_name>
    <phone>(601) 815-5374</phone>
    <email>ddmontgomery@umc.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Monique Cain-Jones</last_name>
    <phone>(601) 815-6639</phone>
    <email>mcain-jones@umc.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Mississippi Medical Center</name>
      <address>
        <city>Jackson</city>
        <state>Mississippi</state>
        <zip>39216</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Angelena N. Sharp, RN</last_name>
      <phone>601-815-9282</phone>
      <email>asharp@umc.edu</email>
    </contact>
    <contact_backup>
      <last_name>Cathy W. Hudgins, RN</last_name>
      <phone>601-815-9276</phone>
      <email>chudgins@umc.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Gailen D. Marshall, Jr., MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 26, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2019</study_first_posted>
  <last_update_submitted>March 28, 2021</last_update_submitted>
  <last_update_submitted_qc>March 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Mississippi Medical Center</investigator_affiliation>
    <investigator_full_name>Gailen D. Marshall Jr., MD PhD</investigator_full_name>
    <investigator_title>The R. Faser Triplett, Sr., MD Chair of Allergy and Immunology, Professor of Medicine, Pediatrics, Pathology and Population Science</investigator_title>
  </responsible_party>
  <keyword>Immulina</keyword>
  <keyword>Natural Killer Cells (NK)</keyword>
  <keyword>Dietary supplementation</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

